Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://creaders.net
Are you over 18 and want to see adult content?
A complete backup of https://generazioniconnesse.it
Are you over 18 and want to see adult content?
A complete backup of https://tostore.jp
Are you over 18 and want to see adult content?
A complete backup of https://pawshake.com.au
Are you over 18 and want to see adult content?
A complete backup of https://livekindly.co
Are you over 18 and want to see adult content?
A complete backup of https://shabbirahsan.com
Are you over 18 and want to see adult content?
A complete backup of https://betsworld.xyz
Are you over 18 and want to see adult content?
A complete backup of https://cogecopeer1.com
Are you over 18 and want to see adult content?
A complete backup of https://4men1lady.com
Are you over 18 and want to see adult content?
A complete backup of https://sentres.com
Are you over 18 and want to see adult content?
A complete backup of https://thecakestore.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://forexinc.ca
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://egowrappin.com
Are you over 18 and want to see adult content?
A complete backup of https://pixhost.to
Are you over 18 and want to see adult content?
A complete backup of https://lyoncapitale.fr
Are you over 18 and want to see adult content?
A complete backup of https://loja2.com.br
Are you over 18 and want to see adult content?
A complete backup of https://permagard.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://viewfromthewing.com
Are you over 18 and want to see adult content?
A complete backup of https://acua.org
Are you over 18 and want to see adult content?
A complete backup of https://bsvu.org
Are you over 18 and want to see adult content?
A complete backup of https://rv.net.cn
Are you over 18 and want to see adult content?
A complete backup of https://kreditrechner-auto.net
Are you over 18 and want to see adult content?
A complete backup of https://mailcow.email
Are you over 18 and want to see adult content?
Text
for
MYCAMINE - ASTELLAS
MYCAMINE 50 mg vial: after reconstitution each mL contains 10 mg of micafungin. MYCAMINE 100 mg vial: after reconstitution each mL contains 20 mg of micafungin. ASTELLAS PHARMA US, INC. Among these issues, a few stand out that have a significant impact on our ability to bring the Astellas Way to life every day for all our stakeholders. Mitigating implicit bias. We will examine how to better identify and then effectively address implicit bias not only in individual behavior, but in systems and processes to strengthen ourbusiness.
ASTELLAS PHARMA US, INC. corporate.communications@astellas.com. 800-888-7704. (press menu option 5, then option 2) This line is monitored between 8:00am-4:30-pm Central Time M-F. For inquiries during non-business hours, please contact us. Astellas on Twitter. HIGHLIGHTS OF PRESCRIBING INFORMATION PADCEV. PADCEV 1 INDICATIONS AND USAGE PADCEV ® is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor -1 (PD-1) or programmed death-ligand 1 (PD -L1) inhibitor, AMEVIVE (ALEFACEPT) DESCRIPTION AMEVIVE® (alefacept) DESCRIPTION AMEVIVE® (alefacept) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. ASTELLAS PHARMA US, INC. Two Astellas employees are working hard to help young adults in the St. Louis metropolitan area and other expanding US cities overcome these odds and successfully navigate their transition from school to working as young business professionals. Larry Blue, senior key account manager, Astellas, and Kendra Neely-Martin, executive rep I,SPC
ASTELLAS APPOINTS PETER SANDOR TO VICE PRESIDENT, ONCOLOGY Astellas recently announced the appointment of Dr. Peter Sandor as vice president, head of oncology therapeutic area in Marketing Strategy. In this role, Sandor will provide strategic commercial ASTELLAS AND SEAGEN ANNOUNCE PHASE 3 TRIAL RESULTS TOKYO and BOTHELL, Wash., Feb. 12, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV ® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were ASTELLAS' XOSPATA® (GILTERITINIB) MEETS OVERALL SURVIVAL COMMODORE is an open-label, randomized study of gilteritinib versus salvage chemotherapy in adult patients who have relapsed or refractory AML in China and other countries. Astellas has stopped enrollment in the trial and patients in the chemotherapy arm will be offered the opportunity to receive gilteritinib. ASTELLAS SUBMITS NEW DRUG APPLICATION FOR ENFORTUMAB Astellas Submits New Drug Application for Enfortumab Vedotin in Japan. TOKYO, March 11, 2021 / PRNewswire / -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotinfor
MYCAMINE - ASTELLAS
MYCAMINE 50 mg vial: after reconstitution each mL contains 10 mg of micafungin. MYCAMINE 100 mg vial: after reconstitution each mL contains 20 mg of micafungin. ASTELLAS PHARMA US, INC. Among these issues, a few stand out that have a significant impact on our ability to bring the Astellas Way to life every day for all our stakeholders. Mitigating implicit bias. We will examine how to better identify and then effectively address implicit bias not only in individual behavior, but in systems and processes to strengthen ourbusiness.
ASTELLAS PHARMA US, INC. corporate.communications@astellas.com. 800-888-7704. (press menu option 5, then option 2) This line is monitored between 8:00am-4:30-pm Central Time M-F. For inquiries during non-business hours, please contact us. Astellas on Twitter. HIGHLIGHTS OF PRESCRIBING INFORMATION PADCEV. PADCEV 1 INDICATIONS AND USAGE PADCEV ® is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor -1 (PD-1) or programmed death-ligand 1 (PD -L1) inhibitor, AMEVIVE (ALEFACEPT) DESCRIPTION AMEVIVE® (alefacept) DESCRIPTION AMEVIVE® (alefacept) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. ASTELLAS PHARMA US, INC. Two Astellas employees are working hard to help young adults in the St. Louis metropolitan area and other expanding US cities overcome these odds and successfully navigate their transition from school to working as young business professionals. Larry Blue, senior key account manager, Astellas, and Kendra Neely-Martin, executive rep I,SPC
ASTELLAS APPOINTS PETER SANDOR TO VICE PRESIDENT, ONCOLOGY Astellas recently announced the appointment of Dr. Peter Sandor as vice president, head of oncology therapeutic area in Marketing Strategy. In this role, Sandor will provide strategic commercial NEW RESEARCH REFLECTS ASTELLAS' COMMITMENT TO ACUTE Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new data in acute myeloid leukemia (AML) at ASTELLAS SUBMITS NEW DRUG APPLICATION FOR ENFORTUMAB TOKYO, March 11, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after ASTELLAS EXPANDS TOP MANAGEMENT, NAMES PERCIVAL BARRETTO Astellas US President Percival Barretto-Ko was promoted to Chief Business Officer, focused on leading the company's new corporate strategic plan and enhancing Astellas' external and internal innovation.; Astellas Institute for Regenerative Medicine President Yoshitsugu Shitaka was promoted to Chief Scientific Officer, with responsibility for operations and the expansion of Astellas' drug ASTELLAS RECEIVES APPROVAL OF EVRENZO® (ROXADUSTAT) IN TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO ® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on ASTELLAS PHARMA US, INC. Among these issues, a few stand out that have a significant impact on our ability to bring the Astellas Way to life every day for all our stakeholders. Mitigating implicit bias. We will examine how to better identify and then effectively address implicit bias not only in individual behavior, but in systems and processes to strengthen ourbusiness.
ASTELLAS PHARMA US, INC. corporate.communications@astellas.com. 800-888-7704. (press menu option 5, then option 2) This line is monitored between 8:00am-4:30-pm Central Time M-F. For inquiries during non-business hours, please contact us. Astellas on Twitter. HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS … 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE VAPRISOL® is indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia. Important Limitations: VAPRISOL has not been shown to be effective for the treatment of the signs and symptoms of ASTELLAS PHARMA US, INC. For recent college graduates, the transition to professional life can prove difficult. About 60 percent of executives and hiring managers believe most college graduates can succeed in entry-level positions, according to a survey from the Association of American Colleges and Universities. 1 However, just one-third of these executives and one quarter of hiring managers surveyed believe these NEW DRUG APPLICATION SUBMITTED FOR RSD1235 FOR IMMEDIATE RELEASE NASDAQ: CRME TSX: COM NEW DRUG APPLICATION SUBMITTED FOR RSD1235 Vancouver, Canada and Deerfield, Illinois, USA, March 31, 2006-- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. todayADMS QD EXTRANET
ADMS QD Extranet - Login. Internal ADMS QD Portal. Astellas QD Extranet. Domain: astellas.net eu.astellas.net. Note: The domain selection should only be changed for those logging in with a user ID that was not migrated to the global Astellas domain. 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information The recommended oral dose of VESIcare is 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be increased ASTELLAS PHARMA US, INC. Among these issues, a few stand out that have a significant impact on our ability to bring the Astellas Way to life every day for all our stakeholders. Mitigating implicit bias. We will examine how to better identify and then effectively address implicit bias not only in individual behavior, but in systems and processes to strengthen ourbusiness.
HIGHLIGHTS OF PRESCRIBING INFORMATION • DISCONTINUE …ENZALUTAMIDE PRESCRIBING INFORMATION 5.6 Embryo-Fetal Toxicity The safety and efficacy of XTANDI have not been established in females. Based on animal reproductive studies and mechanism of action, XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. ASTELLAS PHARMA US, INC. corporate.communications@astellas.com. 800-888-7704. (press menu option 5, then option 2) This line is monitored between 8:00am-4:30-pm Central Time M-F. For inquiries during non-business hours, please contact us. Astellas on Twitter. MYCAMINE - ASTELLASMYCAMINE ANTIBIOTICMYCAMINE IV STABILITYMYCAMINE100 MG IV COST
MYCAMINE 50 mg vial: after reconstitution each mL contains 10 mg of micafungin. MYCAMINE 100 mg vial: after reconstitution each mL contains 20 mg of micafungin. HIGHLIGHTS OF PRESCRIBING INFORMATION • INFUSION-RELATED 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied 16.2 Storage and Handling 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are notlisted.
OINTMENT 0.03% OINTMENT 0.1% 2 Tacrolimus has an empirical formula of C44H69NO12 H2O and a formula weight of 822.03. Each gram of PROTOPIC Ointment contains (w/w) either 0.03% or 0.1% of tacrolimus in a base of mineral oil, paraffin, propylene carbonate, white AMEVIVE (ALEFACEPT) DESCRIPTION AMEVIVE® (alefacept) DESCRIPTION AMEVIVE® (alefacept) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1.ADMS QD EXTRANET
ADMS QD Extranet - Login. Internal ADMS QD Portal. Astellas QD Extranet. Domain: astellas.net eu.astellas.net. Note: The domain selection should only be changed for those logging in with a user ID that was not migrated to the global Astellas domain. ASTELLAS APPOINTS PETER SANDOR TO VICE PRESIDENT, ONCOLOGY Astellas recently announced the appointment of Dr. Peter Sandor as vice president, head of oncology therapeutic area in Marketing Strategy. In this role, Sandor will provide strategic commercial 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information The recommended oral dose of VESIcare is 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be increased ASTELLAS PHARMA US, INC. Among these issues, a few stand out that have a significant impact on our ability to bring the Astellas Way to life every day for all our stakeholders. Mitigating implicit bias. We will examine how to better identify and then effectively address implicit bias not only in individual behavior, but in systems and processes to strengthen ourbusiness.
HIGHLIGHTS OF PRESCRIBING INFORMATION • DISCONTINUE …ENZALUTAMIDE PRESCRIBING INFORMATION 5.6 Embryo-Fetal Toxicity The safety and efficacy of XTANDI have not been established in females. Based on animal reproductive studies and mechanism of action, XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. ASTELLAS PHARMA US, INC. corporate.communications@astellas.com. 800-888-7704. (press menu option 5, then option 2) This line is monitored between 8:00am-4:30-pm Central Time M-F. For inquiries during non-business hours, please contact us. Astellas on Twitter. MYCAMINE - ASTELLASMYCAMINE ANTIBIOTICMYCAMINE IV STABILITYMYCAMINE100 MG IV COST
MYCAMINE 50 mg vial: after reconstitution each mL contains 10 mg of micafungin. MYCAMINE 100 mg vial: after reconstitution each mL contains 20 mg of micafungin. HIGHLIGHTS OF PRESCRIBING INFORMATION • INFUSION-RELATED 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied 16.2 Storage and Handling 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are notlisted.
OINTMENT 0.03% OINTMENT 0.1% 2 Tacrolimus has an empirical formula of C44H69NO12 H2O and a formula weight of 822.03. Each gram of PROTOPIC Ointment contains (w/w) either 0.03% or 0.1% of tacrolimus in a base of mineral oil, paraffin, propylene carbonate, white AMEVIVE (ALEFACEPT) DESCRIPTION AMEVIVE® (alefacept) DESCRIPTION AMEVIVE® (alefacept) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1.ADMS QD EXTRANET
ADMS QD Extranet - Login. Internal ADMS QD Portal. Astellas QD Extranet. Domain: astellas.net eu.astellas.net. Note: The domain selection should only be changed for those logging in with a user ID that was not migrated to the global Astellas domain. ASTELLAS APPOINTS PETER SANDOR TO VICE PRESIDENT, ONCOLOGY Astellas recently announced the appointment of Dr. Peter Sandor as vice president, head of oncology therapeutic area in Marketing Strategy. In this role, Sandor will provide strategic commercial ASTELLAS PHARMA US, INC. This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. ASTELLAS PHARMA US, INC. Astellas Pharma US, Inc. is committed to providing patients, customers, community and employees with a bright future by changing tomorrow. Our commitment is made possible because we are a different kind of pharmaceutical company. This is apparent not only in what we do, but how we do it. ASTELLAS PHARMA US, INC. Astellas Pharma Inc. announced changes in its Global Commercial Leadership Team reporting to Chief Commercial Officer Yukio Matsui aligned with the focuses ASTELLAS AND SEAGEN ANNOUNCE PHASE 3 TRIAL RESULTS TOKYO and BOTHELL, Wash., Feb. 12, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced primary results from the phase 3 EV-301 trial comparing PADCEV ® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were ASTELLAS AND SEATTLE GENETICS RECEIVE FDA BREAKTHROUGH The FDA's Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. ASTELLAS PHARMA US, INC. Among these issues, a few stand out that have a significant impact on our ability to bring the Astellas Way to life every day for all our stakeholders. Mitigating implicit bias. We will examine how to better identify and then effectively address implicit bias not only in individual behavior, but in systems and processes to strengthen ourbusiness.
ASTELLAS PHARMA US, INC. corporate.communications@astellas.com. 800-888-7704. (press menu option 5, then option 2) This line is monitored between 8:00am-4:30-pm Central Time M-F. For inquiries during non-business hours, please contact us. Astellas on Twitter.ADMS QD EXTRANET
ADMS QD Extranet - Login. Internal ADMS QD Portal. Astellas QD Extranet. Domain: astellas.net eu.astellas.net. Note: The domain selection should only be changed for those logging in with a user ID that was not migrated to the global Astellas domain.ASTELLAS PHARMA US
Astellas Announces Key Leadership Changes in Legal, Human Resources. NORTHBROOK, Ill., March 13, 2018 / PRNewswire / -- Astellas today announced three senior-level changes in its global Legal and Human Resources organizations. Roderick (Rod) Christmon is promoted to executive director, Medical & Development, leading the Human Resourcesteam for
ASTELLAS RECEIVES FDA APPROVAL FOR CRESEMBA "We're pleased with the FDA's approval of CRESEMBA for use in treating patients with these life-threatening infections," said Bernie Zeiher, M.D., executive vice president, Global Development and therapeutic area head of Infectious Disease at Astellas."We are proud to be able to offer a new treatment for patients in an area for which there is a significant unmet medical need." Skip to main contentSearch
Search
US
* About
* U.S. Products
* Medical Safety
* Safety Data Sheets (v 3.0)* Philosophy
* Charter of Corporate Conduct * U.S. Corporate Profile* Locations
* Group Code of Conduct* Leadership
* Percival Barretto-Ko* Joe Devaney
* Shontelle Dodson
* Lynn Fenicchia
* Moyra Knight
* Mark Reisenauer
* Steve Sabus
* Regulations
* State Regulations
* California Declaration of Comprehensive Compliance Program * Vermont’s Pharmaceutical Marketer Price Disclosure * Wholesale Acquisition Cost Information for Colorado Prescribers * Consumer Product Safety Commission Regulations* Company Facts
* Astellas Fact Sheet * Corporate Brochure* CSR Report Card
* Policies & Position Statements* Contact Us
* Procurement
* Procurement News
* Prospective Suppliers * Existing Suppliers * Contact & Resources * Authorized Distributors of Records * PO terms and conditions* Vision & Strategy
* Governance
* History
* Political ContributionsRecommended
U.S. Corporate Profile Learn more about Astellas U.S.Read More
* Innovation
* Partnering
* Track Record
* Areas of Interest
* Partnering Inquiry* R&D
* Approach
* Clinical Trials
* Ethics & Principles* Pipeline
Recommended
Clinical Trials
This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any...Read More
* Corporate Responsibility * COVID-19 Relief Response * Commitment To Transparency * U.S. Sunshine Act Overview * Changing Tomorrow Day* CSR Report Card
* Corporate Grants
* Access Accelerated* Employee Impact
* Patient Advocacy
* Awards & RecognitionRecommended
CSR Report Card
The 2017 CSR Report Card reviews our progress and celebrates our achievements over the past year.Read More
* News
* News Releases
* Stories
* Corporate
* Corporate Awards
* Corporate Social Responsibility* Our People
* Therapeutic Area News * The Astellas Way Blog* Feature Stories
* Video Gallery
* Statements
* Media Inquiries
Recommended
Feature Stories
Feature Stories showcase the people and programs that bring to life the Astellas Way values and culture.Read More
STAKEHOLDERS MENU
* Patients & Caregivers * Support for Patients * Astellas Pharma Support Solutions* MyIFI
* Resources and Contacts * Issues that Matter to You* Careers
* Partnering
COMMON HEADER MENU
* ">IMPORTANT NOTICE* WORLDWIDE
* ">US
* WORLDWIDE - US
Important Notice
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those underdevelopment.
Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.I Agree
You are now leaving www.astellas.com/us. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site. Cancel Click here to leave this site.Previous Pause Next
Information About COVID-19 Read MoreCorporate
Social Responsibility Read More1
2
NEWS
* Latest
News / Media
Sep 02, 2019
RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology inOncology Read More
News / Media
Aug 09, 2019
Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification Read MoreNews / Media
Aug 06, 2019
Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor SymptomsRead More
News / Therapeutic Area NewsApr 10, 2020
Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration Read More News / Therapeutic Area NewsFeb 19, 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEVâ„¢ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder CancerRead More
News / Therapeutic Area NewsFeb 11, 2020
XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC Read MoreView All >>
Patients & Caregivers Learn more about resources designed to meet the needs of patients andcaregivers
Read More
Investors
Access financial information, investor relations library, analystcoverage and more
Read More
Contact Us
Call us at (800) 888-7704, M-F, 8AM-7PM CTRead More
HOMEPAGE EXTERNAL LINK Follow us on social mediaBOTTOM FOOTER MENU
* SITE MAP
* PRIVACY POLICY
* ACCESSIBILITY
* LEGAL DISCLAIMER
* CONTACT US
© 2019 Astellas Pharma US, Inc.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0